Abbott Laboratories (NYSE:ABT) Big Money Sentiment Is 0.91

May 16, 2018 - By Samuel McNeil

Abbott Laboratories (NYSE:ABT) Corporate Logo

Abbott Laboratories’s Sentiment

“Big money sentiment for Abbott Laboratories (NYSE:ABT) in 2017 Q4 increased to 0.91, SEC filings reveal. That’s up 0.04, from 2017Q3’s 0.87. 553 investment professionals increased or opened new positions, while 610 reduced and sold their positions in Abbott Laboratories so the sentiment has improved. These funds own 1.22 billion shares, that’s up from 1.21 billion shares in 2017Q3. Funds holding Abbott Laboratories in top 10 decreased from 59 to 58 for a decrease of 1. In total 52 funds closed positions, 558 reduced and 430 increased. Also 123 funds bought new Abbott Laboratories stakes.

Most Abbott Laboratories Investors

As of 2017 Q4 Sector Gamma As has 10.36% invested in Abbott Laboratories. Abbott Laboratories’s shareholder Brandywine Trust Co owns 161,230 shares as of 2017 Q4. Poplar Forest Capital Llc reported 1.21 million shares. The Vermont-based fund Prentiss Smith & Co Inc have invested about 5.37% of the investment professional’s stock portfolio in Abbott Laboratories. The Delaware-based fund Green Valley Investors Llc holds 1.96 million shares or 5.32% of their stocks portfolio.

Abbott Laboratories manufactures and sells health care products worldwide.The company has $106.60 billion market cap. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.226.04 is the P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

ABT is reaching $60.805 during the last trading session, after increased 0.44%.Abbott Laboratories has volume of 2.26 million shares. Since May 16, 2017 ABT has risen 34.85% and is uptrending. ABT outperformed the S&P 500 by 23.30%.

Earnings report for Abbott Laboratories (NYSE:ABT) is anticipated on July, 19., Faxor reports. Last year’s EPS was $0.62, while now analysts expect change of 14.52 % up from current $0.71 EPS. The profit will be $1.24B for ABT if $0.71 EPS becomes true. 20.34 % EPS growth is what analysts predict. $0.59 EPS was reported for previous quarter.

Alphamark Advisors Limited Liability Co reported 100 shs or 0% of all its holdings. Pub Employees Retirement Systems Of Ohio has invested 0.35% in Abbott Laboratories (NYSE:ABT). Jnba Advsr invested 0.22% of its capital in Abbott Laboratories (NYSE:ABT). Cibc Corporation invested 0.21% of its capital in Abbott Laboratories (NYSE:ABT). Voloridge Investment Lc has 0.1% invested in Abbott Laboratories (NYSE:ABT). Brown Brothers Harriman And Communication has 126,537 shs for 0.04% of their capital. Perkins Coie Trust Com has 1,684 shs. Goldman Sachs Grp Inc Inc has 15.77 million shs for 0.22% of their capital. Grantham Mayo Van Otterloo Communications Limited Liability Co invested in 4.82M shs or 1.62% of the stock. Nomura Holdg holds 0.04% or 401,512 shs in its capital. Moreover, Covington Capital Mgmt has 0.66% invested in Abbott Laboratories (NYSE:ABT). South Dakota Investment Council stated it has 78,799 shs or 0.1% of all its holdings. Stonebridge Capital Mngmt Inc accumulated 18,826 shs. Forte Limited Liability Corp Adv holds 6,493 shs. Moreover, Alpha Cubed Ltd Liability Company has 0.13% invested in Abbott Laboratories (NYSE:ABT).

Abbott Laboratories had 20 selling transactions and 1 insider buy since December 14, 2017. This’s net activity of $23.69 million. MANNING JOSEPH J sold 1,430 shs worth $84,344. Salvadori Daniel Gesua Sive sold 905 shs worth $53,369. Another trade for 1,053 shs valued at $62,056 was sold by Bracken Sharon J. 297 shs were sold by Watkin Jared, worth $17,609. On Wednesday, February 28 Fussell Stephen R had sold 11,106 shs worth $667,804. 8,262 shs were sold by BIRD ROGER, worth $518,450 on Friday, March 9.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

In total 14 analysts cover Abbott Laboratories (NYSE:ABT). “Buy” rating has 12, “Sell” are 0, while 2 are “Hold”. (NYSE:ABT) has 86% bullish analysts. 20 are the (NYSE:ABT)’s ratings reports on 16 May 2018 according to StockzIntelligence Inc. On Thursday, January 25 the firm has “Outperform” rating by Wells Fargo given. On Thursday, January 25 Morgan Stanley maintained Abbott Laboratories (NYSE:ABT) with “Overweight” rating. On Thursday, January 25 the stock of Abbott Laboratories (NYSE:ABT) earned “Overweight” rating by JP Morgan. On Tuesday, January 2 the rating was upgraded by JP Morgan to “Overweight”. On Tuesday, April 24 the company was maintained by Citigroup. On Wednesday, January 24 RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating. RBC Capital Markets has “Buy” rating and $67.0 target. The stock rating was maintained by BMO Capital Markets with “Buy” on Wednesday, January 24. In Tuesday, December 12 report BMO Capital Markets upgraded the stock to “Outperform” rating. On Wednesday, April 18 the stock has “Buy” rating by Jefferies. In Thursday, January 25 report Barclays Capital maintained the stock with “Overweight” rating.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: